Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

Novo Nordisk A/S, together with its subsidiaries ... The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart), ...

Embecta's compelling ~44% free cash flow yield offers a strong risk-reward despite headwinds from new insulin technologies ...

While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

See the Zacks Earnings Calendar to stay ahead of market-making news. In the past 60 days, the Zacks Consensus Estimate for Novo Nordisk’s 2024 earnings per share (EPS) declined from $3.28 to $3. ...

On February 14, 2025, the U.S. Food and Drug Administration (“FDA”) approved Sanofi-Aventis U.S. LLC’s (“Sanofi”) MERILOG™ (insulin-aspart-szjj), a biosimilar to Novo Nordisk A/S’s ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is ...